Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJul 14, 2026
DataAggregated Company Financials
Companies65
  • 7D1.1%
  • 3M9.6%
  • 1Y19.7%
  • YTD-4.4%

Over the last 7 days, the Life Sciences industry has risen 1.1%, driven by gains in Danaher and Thermo Fisher Scientific of 3.4% and 2.1%, respectively. Meanwhile, Medpace Holdings actually underperformed within the industry, shrinking 6.2% in the last week. This takes the industry's 12 month performance to a gain of 20%. Looking forward, earnings are forecast to grow by 17% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 15 Jul 2026US$650.5bUS$151.2bUS$13.6b45.4x47.7x4.3x
Fri, 12 Jun 2026US$589.9bUS$150.6bUS$13.8b39.7x42.9x3.9x
Sun, 10 May 2026US$561.7bUS$150.3bUS$14.0b33x40.1x3.7x
Tue, 07 Apr 2026US$561.9bUS$147.8bUS$14.1b37.5x39.9x3.8x
Thu, 05 Mar 2026US$584.0bUS$147.8bUS$14.0b34.9x41.7x4x
Sat, 31 Jan 2026US$662.4bUS$147.0bUS$12.6b34x52.6x4.5x
Mon, 29 Dec 2025US$663.9bUS$145.8bUS$12.5b35.4x53.2x4.6x
Wed, 26 Nov 2025US$678.5bUS$145.6bUS$12.4b37.9x54.8x4.7x
Fri, 24 Oct 2025US$651.0bUS$145.2bUS$14.6b33.4x44.5x4.5x
Sun, 21 Sep 2025US$573.4bUS$144.3bUS$14.6b30.7x39.4x4x
Tue, 19 Aug 2025US$583.4bUS$144.2bUS$14.5b28.8x40.3x4x
Thu, 17 Jul 2025US$524.4bUS$142.9bUS$9.1b35.6x57.4x3.7x
Sat, 14 Jun 2025US$537.5bUS$142.9bUS$9.2b35.7x58.6x3.8x
Mon, 12 May 2025US$505.4bUS$142.8bUS$9.6b34.4x52.7x3.5x
Wed, 09 Apr 2025US$509.1bUS$142.5bUS$9.9b32x51.2x3.6x
Fri, 07 Mar 2025US$602.1bUS$143.1bUS$9.8b41.9x61.7x4.2x
Sun, 02 Feb 2025US$691.5bUS$143.0bUS$10.4b41.1x66.5x4.8x
Tue, 31 Dec 2024US$657.8bUS$142.4bUS$10.2b44.3x64.3x4.6x
Thu, 28 Nov 2024US$660.7bUS$142.4bUS$10.2b44.4x64.6x4.6x
Sat, 26 Oct 2024US$680.4bUS$142.0bUS$8.3b35.4x82.3x4.8x
Mon, 23 Sep 2024US$746.6bUS$141.8bUS$8.5b37.7x87.9x5.3x
Wed, 21 Aug 2024US$746.1bUS$141.9bUS$8.3b38.2x90x5.3x
Fri, 19 Jul 2024US$697.6bUS$141.2bUS$12.2b39.9x57.1x4.9x
Sun, 16 Jun 2024US$695.0bUS$141.3bUS$12.2b37.1x57.1x4.9x
Tue, 14 May 2024US$724.6bUS$141.5bUS$12.6b38.5x57.7x5.1x
Thu, 11 Apr 2024US$742.9bUS$142.0bUS$12.8b43.4x58.1x5.2x
Sat, 09 Mar 2024US$754.1bUS$142.1bUS$12.8b44.5x58.8x5.3x
Mon, 05 Feb 2024US$709.3bUS$147.5bUS$12.5b38.3x56.6x4.8x
Wed, 03 Jan 2024US$706.4bUS$153.9bUS$14.2b37.7x49.8x4.6x
Fri, 01 Dec 2023US$643.6bUS$153.8bUS$14.0b35x45.9x4.2x
Sun, 29 Oct 2023US$565.9bUS$153.8bUS$11.3b29.2x50.3x3.7x
Tue, 26 Sep 2023US$674.7bUS$154.6bUS$11.2b33.7x60.2x4.4x
Thu, 24 Aug 2023US$713.3bUS$154.6bUS$11.2b32.8x63.6x4.6x
Sat, 22 Jul 2023US$741.4bUS$155.5bUS$12.7b29.4x58.4x4.8x
Price to Earnings Ratio

58.4x


Total Market Cap: US$741.4bTotal Earnings: US$12.7bTotal Revenue: US$155.5bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 47.7x which is lower than its 3-year average PE of 56.0x.
  • The industry is trading close to its 3-year average PS ratio of 4.4x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 2.5% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-0.93%
Healthcare-0.85%
Life Sciences1.06%
Clinical Research and Equipment1.06%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$534.073.4%
+US$6.5b		27.8%PE29x
DHR DanaherUS$199.052.5%
+US$3.4b		3.2%PE38.3x
A Agilent TechnologiesUS$135.203.1%
+US$1.1b		19.7%PE27x
TXG 10x GenomicsUS$45.7921.0%
+US$1.0b		274.7%PS9.1x
AVTR AvantorUS$11.2910.7%
+US$744.2m		-11.9%PS1.2x

Latest News

AVTR
US$11.29
Avantor
7D
10.7%
1Y
-11.9%
A
US$135.20
Agilent Technologies
7D
3.1%
1Y
19.7%
RVTY
US$111.21
Revvity
7D
-0.7%
1Y
16.0%
Seeking Alpha • Jul 13

Revvity: Overvalued On Sentiment

Summary Revvity, Inc. trades near 52-week highs, buoyed by sector M&A momentum but faces fundamental headwinds. RVTY's projected 2026 revenues are flat over 2025, underperforming the Life Sciences sector's 11% annual growth outlook. Despite management optimism on margin expansion and share buybacks, RVTY trades at a 22% EV/EBIT premium to the sector median. I see RVTY as a near-term short opportunity, with no merger premium expected and limited sales growth post-divestiture. Read the full article on Seeking Alpha
TEM
US$58.67
Tempus AI
7D
-2.4%
1Y
5.0%
Seeking Alpha • Jul 13

Tempus AI: The Market Is Betting On An Inflection I Can't Yet See

Summary Tempus AI is now trading near my October DCF-derived fair value of $62.55, following a sharp growth deceleration and reduced expectations. TEM’s 2026 guidance implies 25% revenue growth, but persistent cash burn and negative Q1 adjusted EBITDA raise concerns about near-term profitability. The Data business remains the key long-term driver, with 40.5% Y/Y revenue growth and 73.1% non-GAAP margins, but SG&A remains high. I maintain a cautious Hold rating, as the current valuation still demands sustained 20%+ CAGR and a clear inflection to cash generation. Read the full article on Seeking Alpha
ILMN
US$191.20
Illumina
7D
-0.3%
1Y
96.8%
Narrative Update • Jul 13

ILMN: Clinical Sequencing Momentum And Sector Funding Support A Fairly Balanced Outlook

The fair value estimate for Illumina has been raised from $185 to $200, reflecting analysts' higher $200 price targets and their view that the company remains a core genomics infrastructure provider, as sector research points to healthy demand trends and solid customer engagement. Analyst Commentary Recent Street research on Illumina points to an increasingly constructive stance from several bullish analysts, with multiple firms revisiting assumptions on demand, execution, and the role of the company in genomics and broader life sciences tools.
IQV
US$207.83
IQVIA Holdings
7D
-0.2%
1Y
31.8%
Narrative Update • Jul 12

IQV: Future Returns Will Reflect AI Trial Use And Margin Execution Risks

The fair value estimate for IQVIA Holdings has been adjusted from $195.00 to $200.00 as analysts weigh a mix of higher Street price targets up to $249, new short term bullish calls, and more cautious views regarding margin expansion and potential upside drivers. Analyst Commentary Recent Street research on IQVIA Holdings shows a split between bullish calls and more cautious voices, with the fair value estimate sitting below the highest targets and closer to the more restrained views on growth and execution risk.
QGEN
US$41.56
Qiagen
7D
7.3%
1Y
-16.8%
Seeking Alpha • Jul 12

Qiagen: New Launches Signal A Turnaround

Summary Qiagen N.V. is rated a Buy, supported by new product launches and automation initiatives poised to drive revenue growth. QGEN's QIAspirant Connect and partnerships like Inpeco/Diasorin and NVIDIA AI collaboration are expected to offset sluggish QuantiFERON demand and accelerate sales. Management reaffirms 1–2% CER sales growth for FY2026, with new launches already receiving orders and broad market access in sample preparation. QGEN trades at a discount to peers on P/S multiples, yet demonstrates higher forward growth potential, reinforcing bullish upside momentum. Read the full article on Seeking Alpha
DHR
US$199.05
Danaher
7D
2.5%
1Y
3.2%
Seeking Alpha • Jul 10

Danaher Is Getting Better, But The Stock Still Isn't Cheap

Summary Danaher Corporation remains slightly overvalued despite recent share price declines and ongoing operational improvements. Q1/26 results showed modest core revenue growth of 0.5%, with bioprocessing as the primary growth driver and diagnostics continuing to struggle. Current valuation multiples—37x earnings and 25.8x FCF—exceed long-term averages, with intrinsic value estimated at $172.91 per share. I maintain a cautious stance and rate DHR as a hold, citing uncertain long-term double-digit growth prospects and reliance on improved segment performance. Read the full article on Seeking Alpha
TXG
US$45.79
10x Genomics
7D
21.0%
1Y
274.7%
Narrative Update • Jul 09

TXG: Cancer Collaboration And Spatial Rollout Will Support More Constructive Outlook

Analysts have lifted the 10x Genomics fair value estimate from $40.00 to $45.00, reflecting higher Street price targets, including recent moves to $37 at Morgan Stanley, $40 at Barclays, and $45 at Citi. These changes are supported by updated earnings models and growing interest in life science tools.
ABCL
US$6.74
AbCellera Biologics
7D
-12.4%
1Y
71.1%
Narrative Update • Jul 09

ABCL: Jazz Deal And Menopause Program Will Support A Stronger Outlook

The analyst fair value estimate for AbCellera Biologics has been raised from $12.00 to $13.00 as analysts point to the new Jazz Pharmaceuticals agreement, recent rating upgrades, and a more constructive view on the company's long term earnings potential, despite lower modeled revenue growth and a higher future P/E assumption. Analyst Commentary Bullish analysts covering AbCellera Biologics are highlighting the recent agreement with Jazz Pharmaceuticals as an important proof point for the company’s partnership model and revenue opportunity.
TMO
US$534.07
Thermo Fisher Scientific
7D
3.4%
1Y
27.8%
Narrative Update • Jul 09

TMO: AI Tools And Biopharma Collaborations Will Drive Future Performance

Thermo Fisher Scientific's analyst price target has been trimmed slightly, with the fair value estimate moving from $611.56 to about $590.77 as analysts factor in a modestly higher discount rate and slightly softer long term revenue growth and margin assumptions, alongside a mix of cautious sector views and continued confidence in the company's role across life science tools and diagnostics. Analyst Commentary Recent research on Thermo Fisher Scientific shows a mix of optimism and caution, with several firms updating price targets, ratings, and sector views as they reassess growth drivers, capital spending trends, and long term organic growth expectations.
ICLR
US$167.97
ICON
7D
-0.4%
1Y
15.4%
MTD
US$1,314.83
Mettler-Toledo International
7D
1.5%
1Y
12.5%
MEDP
US$536.17
Medpace Holdings
7D
-1.9%
1Y
71.5%
Narrative Update • Jun 29

MEDP: Slower Revenue Outlook And Lower P/E Assumptions Will Pressure Expectations

Analysts have trimmed their price targets on Medpace Holdings, with the updated fair value estimate moving from $500.08 to $443.50 as they factor in slightly higher discount rates, more moderate revenue growth assumptions, a marginally lower profit margin outlook, and a modestly reduced future P/E multiple. Analyst Commentary Recent research updates on Medpace Holdings point to a more cautious stance on valuation, with several firms trimming their price targets even as they recognize the company’s execution strengths and long-term opportunities.
RGEN
US$147.13
Repligen
7D
5.2%
1Y
24.6%
SHC
US$17.78
Sotera Health
7D
-1.3%
1Y
56.2%